Ironwood Pharmaceuticals Inc (IRWD) - Net Assets
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has net assets worth $-161.84 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($285.13 Million) and total liabilities ($446.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRWD capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-161.84 Million |
| % of Total Assets | -56.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -143.21% |
| 10-Year Change | -492.46% |
| Growth Volatility | 674.86 |
Ironwood Pharmaceuticals Inc - Net Assets Trend (2007–2025)
This chart illustrates how Ironwood Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Ironwood Pharmaceuticals Inc (IRWD) total market value.
Annual Net Assets for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual net assets of Ironwood Pharmaceuticals Inc from 2007 to 2025. Also explore Ironwood Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-261.83 Million | +13.11% |
| 2024-12-31 | $-301.33 Million | +12.98% |
| 2023-12-31 | $-346.30 Million | -153.08% |
| 2022-12-31 | $652.38 Million | +7.67% |
| 2021-12-31 | $605.91 Million | +867.29% |
| 2020-12-31 | $62.64 Million | +167.17% |
| 2019-12-31 | $-93.25 Million | +52.51% |
| 2018-12-31 | $-196.37 Million | -2094.02% |
| 2017-12-31 | $9.85 Million | -85.24% |
| 2016-12-31 | $66.72 Million | -29.86% |
| 2015-12-31 | $95.12 Million | +7.42% |
| 2014-12-31 | $88.55 Million | +131.66% |
| 2013-12-31 | $38.23 Million | -73.46% |
| 2012-12-31 | $144.05 Million | +31.13% |
| 2011-12-31 | $109.86 Million | -31.15% |
| 2010-12-31 | $159.55 Million | +153.48% |
| 2009-12-31 | $-298.34 Million | -29.48% |
| 2008-12-31 | $-230.41 Million | -29.17% |
| 2007-12-31 | $-178.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ironwood Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 148421800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $163.00K | % |
| Other Comprehensive Income | $-1.06 Million | % |
| Other Components | $1.41 Billion | % |
| Total Equity | $-261.83 Million | 100.00% |
Ironwood Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acast AB
ST:ACAST
|
$672.54 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
$672.63 Million |
|
Reitir fasteignafélag hf
IC:REITIR
|
$673.08 Million |
|
Anhui Wanyi Science and Technology Co Ltd
SHG:688600
|
$673.36 Million |
|
Oneness Biotech Co Ltd
TWO:4743
|
$672.25 Million |
|
LiJiang YuLong Tourism Co Ltd
SHE:002033
|
$672.21 Million |
|
Chengdu Huaqi Houpu Holding Co Ltd
SHE:300471
|
$672.17 Million |
|
Phenix Optical Co Ltd
SHG:600071
|
$672.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ironwood Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -301,335,000 to -261,834,999, a change of 39,500,001.
- Net income of 24,017,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1,983,000.
- Other factors increased equity by 17,466,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $24.02 Million | +9.17% |
| Other Comprehensive Income | $-1.98 Million | -0.76% |
| Other Changes | $17.47 Million | +6.67% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Ironwood Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $-2.45 | $4.23 | x |
| 2008-12-31 | $-3.38 | $4.23 | x |
| 2009-12-31 | $-4.32 | $4.23 | x |
| 2010-12-31 | $1.78 | $4.23 | x |
| 2011-12-31 | $1.10 | $4.23 | x |
| 2012-12-31 | $1.35 | $4.23 | x |
| 2013-12-31 | $0.33 | $4.23 | x |
| 2014-12-31 | $0.65 | $4.23 | x |
| 2015-12-31 | $0.67 | $4.23 | x |
| 2016-12-31 | $0.46 | $4.23 | x |
| 2017-12-31 | $0.07 | $4.23 | x |
| 2018-12-31 | $-1.29 | $4.23 | x |
| 2019-12-31 | $-0.60 | $4.23 | x |
| 2020-12-31 | $0.39 | $4.23 | x |
| 2021-12-31 | $3.69 | $4.23 | x |
| 2022-12-31 | $3.50 | $4.23 | x |
| 2023-12-31 | $-2.23 | $4.23 | x |
| 2024-12-31 | $-1.88 | $4.23 | x |
| 2025-12-31 | $-1.47 | $4.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ironwood Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.11%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-118.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -504.13% | 0.08x | 0.00x | $-34.27 Million |
| 2008 | 0.00% | -242.50% | 0.16x | 0.00x | $-30.30 Million |
| 2009 | 0.00% | -197.18% | 0.22x | 0.00x | $-41.03 Million |
| 2010 | -33.21% | -120.80% | 0.15x | 1.89x | $-68.94 Million |
| 2011 | -59.03% | -98.45% | 0.32x | 1.90x | $-75.84 Million |
| 2012 | -50.42% | -48.34% | 0.65x | 1.60x | $-87.03 Million |
| 2013 | -713.70% | -1192.31% | 0.08x | 7.30x | $-276.63 Million |
| 2014 | -214.13% | -248.07% | 0.23x | 3.77x | $-198.47 Million |
| 2015 | -149.98% | -95.40% | 0.24x | 6.51x | $-152.18 Million |
| 2016 | -122.47% | -29.83% | 0.39x | 10.64x | $-88.38 Million |
| 2017 | -1187.42% | -39.20% | 0.49x | 61.50x | $-117.92 Million |
| 2018 | 0.00% | -81.46% | 1.04x | 0.00x | $-262.73 Million |
| 2019 | 0.00% | 5.02% | 1.06x | 0.00x | $30.83 Million |
| 2020 | 169.50% | 27.26% | 0.70x | 8.93x | $99.91 Million |
| 2021 | 87.22% | 127.72% | 0.37x | 1.86x | $467.86 Million |
| 2022 | 26.83% | 42.64% | 0.37x | 1.69x | $109.83 Million |
| 2023 | 0.00% | -226.37% | 0.94x | 0.00x | $-967.61 Million |
| 2024 | 0.00% | 0.25% | 1.00x | 0.00x | $31.01 Million |
| 2025 | 0.00% | 8.11% | 0.75x | 0.00x | $50.20 Million |
Industry Comparison
This section compares Ironwood Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $180,509,986
- Average return on equity (ROE) among peers: -187.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc (IRWD) | $-161.84 Million | 0.00% | N/A | $672.53 Million |
| Aurora Cannabis Inc (ACB) | $219.71 Million | -5.90% | 0.47x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-185.83 Million | 0.00% | 0.00x | $134.82 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $5.23 Million | -1801.64% | 67.08x | $239.89 Million |
| Alkermes Plc (ALKS) | $853.85 Million | 2.93% | 0.68x | $7.84 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.58 Billion |
| Amphastar P (AMPH) | $281.86 Million | -3.80% | 0.38x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $5.96 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $94.76 Million | 8.93% | 0.40x | $279.44 Million |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more